Corvus Pharmaceuticals, Inc.
CRVS
$3.24
$0.010.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 51.96M | 41.65M | 47.25M | 22.13M | 27.15M |
| Total Receivables | 216.00K | 221.00K | 122.00K | 58.00K | 63.00K |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 470.00K | 388.00K | 504.00K | 247.00K | 375.00K |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 1.76M | 661.00K | 386.00K | 418.00K | 369.00K |
| Total Current Assets | 54.41M | 42.92M | 48.26M | 22.85M | 27.96M |
|
|
|||||
| Total Current Assets | 54.41M | 42.92M | 48.26M | 22.85M | 27.96M |
| Net Property, Plant & Equipment | 1.33M | 455.00K | 770.00K | 1.08M | 1.39M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 632.00K | 252.00K | 129.00K | 89.00K | 89.00K |
| Total Assets | 68.91M | 58.82M | 64.56M | 40.08M | 45.55M |
|
|
|||||
| Total Accounts Payable | 2.58M | 1.87M | 1.21M | 1.61M | 1.53M |
| Total Accrued Expenses | 3.44M | 3.81M | 4.07M | 3.89M | 3.73M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 185.00K | 354.00K | 700.00K | 1.04M | 1.37M |
| Total Finance Division Other Current Liabilities | 29.20M | 40.37M | 7.35M | 179.00K | 245.00K |
| Total Other Current Liabilities | 29.20M | 40.37M | 7.35M | 179.00K | 245.00K |
| Total Current Liabilities | 35.40M | 46.41M | 13.34M | 6.72M | 6.87M |
|
|
|||||
| Total Current Liabilities | 35.40M | 46.41M | 13.34M | 6.72M | 6.87M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 937.00K | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 36.34M | 46.41M | 13.34M | 6.72M | 6.87M |
|
|
|||||
| Common Stock & APIC | 430.87M | 398.04M | 397.26M | 375.06M | 374.37M |
| Retained Earnings | -397.01M | -384.90M | -344.68M | -340.42M | -334.72M |
| Treasury Stock & Other | -1.29M | -738.00K | -1.36M | -1.28M | -967.00K |
| Total Common Equity | 32.57M | 12.41M | 51.23M | 33.36M | 38.68M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 32.57M | 12.41M | 51.23M | 33.36M | 38.68M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 32.57M | 12.41M | 51.23M | 33.36M | 38.68M |
|
|
|||||